Drugs / NNC9204-1177
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04059367 | Aug 2019 → Jan 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03308721 | Oct 2017 → Jan 2020 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02941042 | Oct 2016 → Sep 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC9204-1177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03308721 ↗ |
| Route | Subcutaneous | “A single dose administered subcutaneously ( s.c. under the skin)” NCT02941042 ↗ |